JP2012507033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012507033A5 JP2012507033A5 JP2011534536A JP2011534536A JP2012507033A5 JP 2012507033 A5 JP2012507033 A5 JP 2012507033A5 JP 2011534536 A JP2011534536 A JP 2011534536A JP 2011534536 A JP2011534536 A JP 2011534536A JP 2012507033 A5 JP2012507033 A5 JP 2012507033A5
- Authority
- JP
- Japan
- Prior art keywords
- spectrum
- monoclonal antibody
- growth factor
- factor receptor
- epidermal growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 8
- 238000001228 spectrum Methods 0.000 claims 6
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 102000001301 EGF receptor Human genes 0.000 claims 4
- 108060006698 EGF receptor Proteins 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 238000001819 mass spectrum Methods 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 238000007635 classification algorithm Methods 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 238000010606 normalization Methods 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 238000007781 pre-processing Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/321,394 US7858390B2 (en) | 2006-03-31 | 2009-01-20 | Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway |
| US12/321,394 | 2009-01-20 | ||
| PCT/US2009/006267 WO2010085234A1 (en) | 2009-01-20 | 2009-11-20 | Selection of colorectal cancer patients for treatment with drugs targeting egfr pathway |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012507033A JP2012507033A (ja) | 2012-03-22 |
| JP2012507033A5 true JP2012507033A5 (enExample) | 2012-05-10 |
| JP4997345B2 JP4997345B2 (ja) | 2012-08-08 |
Family
ID=41571343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534536A Expired - Fee Related JP4997345B2 (ja) | 2009-01-20 | 2009-11-20 | Ｅｇｆｒ経路を標的にする薬物による治療のための結腸直腸癌患者の選択 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7858390B2 (enExample) |
| EP (1) | EP2347261B1 (enExample) |
| JP (1) | JP4997345B2 (enExample) |
| KR (1) | KR101131231B1 (enExample) |
| AU (1) | AU2009338173B2 (enExample) |
| CA (1) | CA2744394A1 (enExample) |
| ES (1) | ES2392805T3 (enExample) |
| IL (1) | IL211944A (enExample) |
| TW (1) | TWI366671B (enExample) |
| WO (1) | WO2010085234A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906342B2 (en) | 2006-03-31 | 2011-03-15 | Biodesix, Inc. | Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples |
| US7858390B2 (en) | 2006-03-31 | 2010-12-28 | Biodesix, Inc. | Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway |
| US7736905B2 (en) | 2006-03-31 | 2010-06-15 | Biodesix, Inc. | Method and system for determining whether a drug will be effective on a patient with a disease |
| WO2011106084A1 (en) * | 2010-02-24 | 2011-09-01 | Biodesix, Inc. | Cancer patient selection for administration of therapeutic agents using mass spectral analysis |
| WO2012102829A1 (en) | 2011-01-28 | 2012-08-02 | Biodesix, Inc. | Predictive test for selection of metastatic breast cancer patients for hormonal and combination therapy |
| SG11201408652SA (en) | 2012-06-26 | 2015-01-29 | Biodesix Inc | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| US8718996B2 (en) | 2012-07-05 | 2014-05-06 | Biodesix, Inc. | Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents |
| TW201621315A (zh) | 2014-12-03 | 2016-06-16 | 拜歐迪希克斯公司 | 使用ｍａｌｄｉ－ｔｏｆ質譜分析以早期偵測高風險群中之肝細胞癌 |
| US10007766B2 (en) | 2015-07-13 | 2018-06-26 | Biodesix, Inc. | Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods |
| BR112018014870A2 (pt) * | 2016-01-21 | 2018-12-11 | Protein Dynamic Solutions Llc | método e sistema para análise de dados espectrais |
| US11710539B2 (en) | 2016-02-01 | 2023-07-25 | Biodesix, Inc. | Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy |
| US11621057B2 (en) | 2016-04-08 | 2023-04-04 | Biodesix, Inc. | Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy |
| CN110383069A (zh) * | 2017-01-05 | 2019-10-25 | 佰欧迪塞克斯公司 | 用于鉴定总体不良预后亚组中持久受益于免疫疗法的癌症患者的方法 |
| JP7565795B2 (ja) | 2017-12-15 | 2024-10-11 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法 |
| US12094587B2 (en) | 2018-03-29 | 2024-09-17 | Biodesix, Inc. | Apparatus and method for identification of primary immune resistance in cancer patients |
| US20230386662A1 (en) * | 2020-10-19 | 2023-11-30 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Rapid and direct identification and determination of urine bacterial susceptibility to antibiotics |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ562192A (en) | 2002-08-06 | 2009-07-31 | Ciphergen Biosystems Inc | Use of biomarkers for detecting ovarian cancer |
| CA2527321A1 (en) * | 2003-05-30 | 2004-12-23 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| US20050267689A1 (en) * | 2003-07-07 | 2005-12-01 | Maxim Tsypin | Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications |
| US20050048547A1 (en) * | 2003-07-17 | 2005-03-03 | Hongyu Zhao | Classification of disease states using mass spectrometry data |
| US20090204334A1 (en) | 2004-03-30 | 2009-08-13 | Eastern Virginia Medical School | Lung cancer biomarkers |
| US20060029574A1 (en) * | 2004-08-06 | 2006-02-09 | Board Of Regents, The University Of Texas System | Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity |
| EP1913157B2 (en) * | 2005-06-28 | 2016-10-26 | Genentech, Inc. | Egfr and kras mutations for prediction of patient response to egfr inhibitor treatment |
| US7908091B2 (en) * | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
| US7858390B2 (en) | 2006-03-31 | 2010-12-28 | Biodesix, Inc. | Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway |
| US7736905B2 (en) * | 2006-03-31 | 2010-06-15 | Biodesix, Inc. | Method and system for determining whether a drug will be effective on a patient with a disease |
-
2009
- 2009-01-20 US US12/321,394 patent/US7858390B2/en not_active Expired - Fee Related
- 2009-11-20 CA CA2744394A patent/CA2744394A1/en not_active Abandoned
- 2009-11-20 AU AU2009338173A patent/AU2009338173B2/en not_active Ceased
- 2009-11-20 JP JP2011534536A patent/JP4997345B2/ja not_active Expired - Fee Related
- 2009-11-20 KR KR1020117007641A patent/KR101131231B1/ko not_active Expired - Fee Related
- 2009-11-20 ES ES09795836T patent/ES2392805T3/es active Active
- 2009-11-20 WO PCT/US2009/006267 patent/WO2010085234A1/en not_active Ceased
- 2009-11-20 EP EP09795836A patent/EP2347261B1/en not_active Not-in-force
- 2009-12-16 TW TW098143181A patent/TWI366671B/zh not_active IP Right Cessation
-
2011
- 2011-03-24 IL IL211944A patent/IL211944A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011513728A5 (enExample) | ||
| Onaitis et al. | Prediction of long-term survival after lung cancer surgery for elderly patients in The Society of Thoracic Surgeons General Thoracic Surgery Database | |
| Quezada et al. | Omics-based biomarkers: current status and potential use in the clinic | |
| Lima et al. | Segregation of ovarian cancer stage exploiting spectral biomarkers derived from blood plasma or serum analysis: ATR‐FTIR spectroscopy coupled with variable selection methods | |
| JP2011506917A5 (enExample) | ||
| JP2015528110A5 (enExample) | ||
| JP2013520681A5 (enExample) | ||
| IL204922A0 (en) | Methods for detecting major adverse cardiovascular and cerebrovascular events | |
| WO2008127376A3 (en) | Biological cell sorting and characterization using aerosol mass spectrometry | |
| WO2007109881A8 (en) | Biomarkers useful for diagnosing prostate cancer, and methods thereof | |
| BR0312534A (pt) | método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura | |
| WO2012047899A3 (en) | Novel dna hypermethylation diagnostic biomarkers for colorectal cancer | |
| EP2707710A1 (en) | Diagnosis of cancer | |
| JP2011516046A5 (enExample) | ||
| JP2009534667A5 (enExample) | ||
| WO2009074276A3 (en) | Marker panel for colorectal cancer | |
| Mazzone et al. | Progress in the development of volatile exhaled breath signatures of lung cancer | |
| GB2494580A (en) | Method for diagnosing lung cancer | |
| CN106092990A (zh) | 一种宁夏枸杞的三维荧光光谱鉴别方法 | |
| WO2015100459A3 (en) | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies | |
| WO2010037859A3 (en) | Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family | |
| Yang et al. | Decreased macrophage inflammatory protein (MIP)‐1α and MIP‐1β increase the risk of developing nasopharyngeal carcinoma | |
| Xu et al. | Serum analysis method combining cellulose acetate membrane purification with surface‐enhanced Raman spectroscopy for non‐invasive HBV screening | |
| WO2005031301A3 (en) | Raman signature probes and their use in the detection and imaging of molecular processes and structures | |
| Michalčíková et al. | A selected ion flow tube study of the ion molecule association reactions of protonated (MH+), nitrosonated (MNO+) and dehydroxidated (M− OH)+ carboxylic acids (M) with H2O |